Exhibit 99.1 nuron 31 DECEMBER 2022 HALF YEAR REPORT | | 31 December | 31 December | | --- | --- | --- | | | 2022 | 2021 | | | Cents | Cents | | Net tangible asset backing (per share) | 9.25 | 10.51 | The calculation of net tangible assets excludes right-of-use assets arising from AASB 16 Leases. Explanation of results An explanation of the key financial elements contributing to the revenue and result above can be found in the review of operations included within the directors' report. Distributions No divi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

y n o e s u l a n o s r e p r o F 11 Immuron INVESTOR PRESENTATION FY22 RESULTS & BUSINESS UPDATE 31 AUGUST, 2022 Steven Lydeamore - CEO NASDAQ: IMRN ASX: IMC EXECUTIVE SUMMARY y n o e s u l a n o s r e p r o F 22 Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases | --- | --- | --- | |--------------------|-------------|-------------------------------------------- ...

Immuron Limited (NASDAQ:IMRN) Q4 2022 Earnings Conference Call September 6, 2022 7:00 PM ET Company Participants Steven Lydeamore - Chief Executive Officer Conference Call Participants Unidentified Company Representative Good morning, everyone. And welcome to Immuron’s Full Year Results Webinar. Today is Wednesday, the 7th of September, 2022. I'd like to welcome the CEO, Steven Lydeamore to provide a brief overview of the results before we move to a Q&A. If you'd like to submit a question, please do so via ...

Exhibit 99.1 Immuron Limited Appendix 4E 30 June 2022 Immuron Limited Appendix 4E Preliminary Final Report Year ended 30 June 2022 | Name of entity: | Immuron Limited | | --- | --- | | ABN: | 80 063 114 045 | | Year ended: | 30 June 2022 | | Previous period: | 30 June 2021 | Results for announcement to the market | | | | $ | | --- | --- | --- | --- | | Revenue from ordinary activities | Up | 424.9% to | 765,193 | | Loss from ordinary activities after tax attributable to members | Down | (66.0)% to | (2,854, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...